3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
2
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Leukemia
7
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Myeloid
2
Gastrointestinal Stromal Tumors
2
Bone Marrow Diseases
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Blast Crisis
1
Interventions
ponatinib
2
nilotinib
2
Imatinib Mesylate
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
pembrolizumab
1
ibrutinib
1
Sertraline
1
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
1
Biopsy
1
BID protein, human
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Bone Marrow Diseases
×
nilotinib
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts
NCT00519090
2011-11-07
ENEST
Novartis
Phase 3
Terminated
6 enrolled
6 charts